RT
Rajat Thawani
Oregon Health & Science University, University of Chicago Medicine, University College of Medical Sciences, Maimonides Medical Center
Research areas: Medicine · Pulmonary and Respiratory Medicine · Radiomics and Machine Learning in Medical Imaging · Cancer Immunotherapy and Biomarkers · Lung Cancer Diagnosis and Treatment
0000-0002-5378-9434
Employment
-
Oregon Health & Science University Assistant Professor of Medicine2025 - Present
-
University of Chicago Medicine Assistant Professor2023 - 2025
- 2020 - 2023
-
Maimonides Medical Center Resident Physician2017 - 2020
-
Case Western Reserve University School of Medicine Research Associate2016 - 2017
-
Indraprastha Apollo Hospitals Clinical Associate2015 - 2016
-
Indraprastha Apollo Hospital Resident Doctor2014 - 2015
-
Guru Teg Bahadur Hospital Medical Intern2012 - 2013
Education
- 2007 - 2014
Projects & Funding
Projects & funding information is unavailable.
Publications (60)
- Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated SCLC: A Case Report Save
- Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC) Save
- Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies Save
- Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies Save
- Clinically Explainable Prediction of Immunotherapy Response Integrating Radiomics and Clinico-Pathological Information in Non-Small Cell Lung Cancer Save
- Dosing immune-checkpoint inhibitors: Opportunities for the future Save
- SUPE_R Surveillance? PET/CT in Post-Treatment NSCLC and the Imperative of Proof Before Practice Save
- Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non–Small Cell Lung Cancer Save
- Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives Save
- Time to rethink platinum choices in the era of immunotherapy in lung cancer Save
- Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers Save
- TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers Save
- Current perspectives of KRAS in non-small cell lung cancer Save
- Plasma cfDNA in Carcinoma of unknown primary: A case series Save
- Data from Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer Save
- Data from Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer Save
- Supplementary Figures from Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer Save
- Supplementary Figures from Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer Save
- Supplementary Tables from Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer Save
- Supplementary Tables from Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer Save